Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estramustine in malignant glioma

A T Bergenheim1, R Henriksson, J M Piepmeier

  • 1Department of Oncology, Umea University, Sweden.

Journal of Neuro-Oncology
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer in young adulthood - classifying the intensity of treatment.

Acta oncologica (Stockholm, Sweden)·2022
Same author

Primary melanotic tumors of the nervous system: a consecutive case series.

European journal of neurology·2020
Same author

Age and surgical outcome of low-grade glioma in Sweden.

Acta neurologica Scandinavica·2018
Same author

The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy.

Neoplasma·2017
Same author

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.

Neuropathology and applied neurobiology·2017

Estramustine shows potent anti-glioma effects by inhibiting proliferation and enhancing radiation sensitivity. This drug targets malignant glioma cells selectively, sparing normal brain cells, and warrants further research for brain tumor treatment.

Area of Science:

  • Oncology
  • Neuro-oncology
  • Pharmacology

Background:

  • Estramustine, a combination of 17 beta-estradiol and nornitrogen mustard, is approved for advanced prostate cancer.
  • Preclinical studies indicate estramustine's potential against human malignant glioma.

Purpose of the Study:

  • To summarize preclinical findings on estramustine's efficacy against malignant gliomas.
  • To explore estramustine's mechanisms of action and selective toxicity.

Main Methods:

  • In vitro and in vivo studies assessing antiproliferative and antimitotic effects.
  • Investigation of estramustine-binding protein expression in glioma cells.
  • Evaluation of estramustine's impact on DNA synthesis, apoptosis, and radiosensitization.

Related Experiment Videos

Main Results:

  • Estramustine exhibits potent antiproliferative and antimitotic activity against malignant glioma cells.
  • Selective toxicity observed: estramustine inhibits glioma cells but not normal astrocytes.
  • Malignant gliomas show higher expression of estramustine-binding protein.
  • Estramustine enhances radiation cytotoxicity in glioma cells and improves outcomes in a rat glioma model.
  • Additional mechanisms include DNA synthesis inhibition and apoptosis induction.

Conclusions:

  • Estramustine demonstrates significant preclinical efficacy against malignant gliomas through multiple mechanisms.
  • Selective targeting of glioma cells via estramustine-binding protein suggests therapeutic potential.
  • Further laboratory and clinical investigations are recommended for estramustine in malignant glioma treatment.